Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Therapy With Biologic Agents After Diagnosis of Solid Malignancies: Results From the Corrona Registry.

Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt NA.

J Rheumatol. 2019 Apr 1. pii: jrheum.171457. doi: 10.3899/jrheum.171457. [Epub ahead of print]

2.

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.

Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB.

Arthritis Rheumatol. 2019 Feb 12. doi: 10.1002/art.40851. [Epub ahead of print]

PMID:
30747501
3.

Utility of administrative and clinical data to predict major change in medical treatment in US Veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry.

Stever JR, Cannon GW, Teng CC, Accortt NA, Collier DH, Sauer BC.

Clin Exp Rheumatol. 2018 Nov 12. [Epub ahead of print]

PMID:
30418115
4.

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).

Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, Collier DH, Chung JB.

RMD Open. 2018 Feb 3;4(1):e000606. doi: 10.1136/rmdopen-2017-000606. eCollection 2018.

5.

Defining and characterizing sustained remission in patients with rheumatoid arthritis.

Curtis JR, Trivedi M, Haraoui B, Emery P, Park GS, Collier DH, Aras GA, Chung J.

Clin Rheumatol. 2018 Apr;37(4):885-893. doi: 10.1007/s10067-017-3923-z. Epub 2017 Dec 9.

6.

Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.

J Rheumatol. 2018 Jan;45(1):78-82. doi: 10.3899/jrheum.161567. Epub 2017 Oct 1.

PMID:
28966209
7.

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.

Reed GW, Collier DH, Koenig AS, Saunders KC, Pappas DA, Litman HJ, Kremer JM, Kotak S.

Arthritis Res Ther. 2017 Apr 27;19(1):81. doi: 10.1186/s13075-017-1289-x.

8.

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.

Clin Rheumatol. 2017 Apr;36(4):895-901. doi: 10.1007/s10067-017-3593-x. Epub 2017 Mar 7.

PMID:
28271234
9.

Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.

Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, Iles J, Stolshek BS, Kaliyaperumal A, Papp KA.

Br J Dermatol. 2017 Aug;177(2):411-418. doi: 10.1111/bjd.15381. Epub 2017 Jul 19.

PMID:
28196270
10.

Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.

Mease PJ, Lesperance T, Liu M, Collier DH, Mason M, Deveikis S, Accortt NA.

J Rheumatol. 2017 Feb;44(2):184-192. doi: 10.3899/jrheum.160343. Epub 2017 Jan 15.

PMID:
28089969
11.

A novel electromechanical autoinjector, AutoTouch™, for self-injection of etanercept: real-world use and benefits.

Collier DH, Bitman B, Coles A, Liu L, Kumar S, Judd C.

Postgrad Med. 2017 Jan;129(1):118-125. doi: 10.1080/00325481.2017.1251291. Epub 2016 Nov 9.

PMID:
27829325
12.

The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis.

Deodhar A, Bitman B, Yang Y, Collier DH.

Clin Rheumatol. 2016 Dec;35(12):3045-3052. Epub 2016 Oct 5.

13.

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.

Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC.

Adv Ther. 2016 Aug;33(8):1347-59. doi: 10.1007/s12325-016-0371-0. Epub 2016 Jun 28.

14.

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.

Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD.

RMD Open. 2015 Dec 30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181. eCollection 2015.

15.

Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, Collier DH, Kricorian G, Langley RG.

J Am Acad Dermatol. 2016 Feb;74(2):280-7.e1-3. doi: 10.1016/j.jaad.2015.09.056.

16.

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.

Accortt NA, Bonafede MM, Collier DH, Iles J, Curtis JR.

Arthritis Rheumatol. 2016 Jan;68(1):67-76. doi: 10.1002/art.39416.

17.

Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.

Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1656-63. doi: 10.1002/acr.22638.

18.

Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.

Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH.

J Manag Care Spec Pharm. 2015 Apr;21(4):318-29.

19.

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy.

Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, Collier DH.

Springerplus. 2015 Mar 5;4:113. doi: 10.1186/s40064-015-0895-9. eCollection 2015.

20.

Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).

Gibofsky A, Cannon GW, Harrison DJ, Joseph GJ, Bitman B, Chaudhari S, Collier DH.

Clin Exp Rheumatol. 2015 May-Jun;33(3):297-301. Epub 2015 Feb 18.

PMID:
25738333
21.

Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.

Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC.

J Rheumatol. 2014 Oct;41(10):1935-43. doi: 10.3899/jrheum.140164. Epub 2014 Aug 15.

22.

Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.

Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, Yun H, Joseph GJ, Collier DH.

Clin Ther. 2014 Jul 1;36(7):996-1004. doi: 10.1016/j.clinthera.2014.05.062. Epub 2014 Jul 8.

PMID:
25012729
23.

Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.

Cannon GW, Wang BC, Park GS, Koenig A, Collier DH, Keystone EC.

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):919-25. Epub 2013 Nov 14.

PMID:
24237999
24.

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE.

Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.

25.

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE.

Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi: 10.1136/annrheumdis-2013-204424.

PMID:
24092682
26.

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.

Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Czirják L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA Jr, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, Silver R, Steen V, Tyndall A, Matucci-Cerinic M, Pope JE, Khanna D.

Arthritis Care Res (Hoboken). 2012 Mar;64(3):351-7. doi: 10.1002/acr.20679.

27.

Limited health literacy is a common finding in a public health hospital's rheumatology clinic and is predictive of disease severity.

Hirsh JM, Boyle DJ, Collier DH, Oxenfeld AJ, Nash A, Quinzanos I, Caplan L.

J Clin Rheumatol. 2011 Aug;17(5):236-41. doi: 10.1097/RHU.0b013e318226a01f.

PMID:
21778910
28.

Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension.

Meadows CA, Risbano MG, Zhang L, Geraci MW, Tuder RM, Collier DH, Bull TM.

Chest. 2011 May;139(5):994-1002. doi: 10.1378/chest.10-0302. Epub 2010 Sep 9.

29.

Health literacy predicts the discrepancy between patient and provider global assessments of rheumatoid arthritis activity at a public urban rheumatology clinic.

Hirsh JM, Boyle DJ, Collier DH, Oxenfeld AJ, Caplan L.

J Rheumatol. 2010 May;37(5):961-6. doi: 10.3899/jrheum.090964. Epub 2010 Mar 15.

PMID:
20231210
30.

A concise evaluation and management curriculum for physicians in training improved billing at an outpatient academic rheumatology clinic.

Hirsh JM, Collier DH, Boyle DJ, Gardner EM.

J Clin Rheumatol. 2010 Apr;16(3):148-50. doi: 10.1097/RHU.0b013e3181d527dc.

PMID:
20216332
31.

Anticardiolipin antibodies in scleroderma.

Enzenauer RJ, Collier DH, Lopez LR.

J Clin Rheumatol. 2006 Dec;12(6):324-6. No abstract available.

PMID:
17149072
32.

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium.

J Rheumatol. 2005 May;32(5):832-40.

PMID:
15868618
33.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2002 Sep;46(9):2410-20.

34.

Three generations of patients with lupus erythematosus and hereditary angioedema.

Pacheco TR, Weston WL, Giclas PC, Collier DH, Lee LA.

Am J Med. 2000 Aug 15;109(3):256-7. No abstract available.

PMID:
11023436
35.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.

Arthritis Rheum. 1998 Apr;41(4):670-7.

PMID:
9550476
36.

Developmental shifts in the ability of infants with Down syndrome to produce treadmill steps.

Ulrich BD, Ulrich DA, Collier DH, Cole EL.

Phys Ther. 1995 Jan;75(1):14-23.

PMID:
7809193
37.

Alternating stepping patterns: hidden abilities of 11-month-old infants with Down syndrome.

Ulrich BD, Ulrich DA, Collier DH.

Dev Med Child Neurol. 1992 Mar;34(3):233-9.

PMID:
1532783
38.

Hypertrophic osteoarthropathy associated with achalasia.

Collier DH, Zulman JI.

Am J Med. 1986 Aug;81(2):355-60.

PMID:
3740092
39.

Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis.

Levine JD, Collier DH, Basbaum AI, Moskowitz MA, Helms CA.

J Rheumatol. 1985 Jun;12(3):406-11. Review.

PMID:
2413204
40.

Anticollagen antibodies and immune response gene products in rheumatoid arthritis.

Collier DH, Kerwar SS, Garovoy MR, Fye KH, Stobo JD.

Arthritis Rheum. 1984 Nov;27(11):1201-9.

PMID:
6437412

Supplemental Content

Loading ...
Support Center